These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 16123492

  • 1. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T.
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [Abstract] [Full Text] [Related]

  • 2. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 3. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Nov; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 4. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y, Okumura KI, Yoshida N, Tayama K, Takemura Y, Inukai T.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [Abstract] [Full Text] [Related]

  • 7. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 8. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y.
    Metabolism; 2002 Apr 08; 51(4):471-6. PubMed ID: 11912556
    [Abstract] [Full Text] [Related]

  • 9. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
    Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC, ADOPT Study Group.
    Diabetes; 2006 Aug 08; 55(8):2357-64. PubMed ID: 16873701
    [Abstract] [Full Text] [Related]

  • 10. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 08; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 11. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 08; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 12. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 08; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 13. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 08; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 14. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 May 08; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 15. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 08; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 16. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
    Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y.
    J Clin Endocrinol Metab; 2002 Feb 08; 87(2):660-5. PubMed ID: 11836301
    [Abstract] [Full Text] [Related]

  • 17. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 18. Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
    Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Auteri A, Bruni F.
    Int J Clin Pharmacol Res; 2001 Jun 06; 21(3-4):147-55. PubMed ID: 12067144
    [Abstract] [Full Text] [Related]

  • 19. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
    Adali E, Yildizhan R, Kurdoglu M, Bugdayci G, Kolusari A, Sahin HG.
    Fertil Steril; 2010 Jul 06; 94(2):666-72. PubMed ID: 19368913
    [Abstract] [Full Text] [Related]

  • 20. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M, Zegura B, Guzic-Salobir B, Keber I.
    Wien Klin Wochenschr; 2001 Feb 15; 113(3-4):113-8. PubMed ID: 11253736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.